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lated quality of life (HQL). METHODS: The SF-36
Health Survey (SF-36) was self-administered by 632 par-
ticipants of a double-blinded, randomized controlled
clinical trial of three treatments for RA. The burden of
early RA (3 years) on HQL was estimated by compar-
ing SF-36 scale scores with general US population norms
and benchmarks for 6 chronic conditions: diabetes, de-
pression, congestive heart failure (CHF), asthma, chronic
obstructive pulmonary disease (COPD) and osteoarthritis
(OA). General US population norms and disease specific
benchmarks were adjusted to the age, gender and race of
the early RA patients. RESULTS: SF-36 scale scores were
significantly (P  0.0001) lower for early RA patients,
relative to age, gender and race adjusted general US pop-
ulation norms. Scales measuring physical health status
were most affected by early RA compared to scales mea-
suring mental health status. Scale scores of early RA pa-
tients were as low or lower than those observed for pa-
tients with CHF, diabetes, OA, COPD, and asthma.
Early RA scores on mental health were better than those
observed for patients with depression. CONCLUSIONS:
HQL measures are helpful in quantifying the impact of
early RA on patient functioning and well being. Early RA
patients report substantially diminished functioning and
well being, compared to the general US population. Pa-
tients with early RA reported health status and function-
ing at least as low as patients commonly considered to
have more debilitating diseases.
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Non-steroid anti-inflammatory drugs (NSAID) are widely
used in Russia in all fields of medicine. At the same time
they produce serious side effects such as gastric or duode-
nal ulcer and gastrointestinal bleeding, that may influ-
ence the cost of illness. OBJECTIVE: The study purpose
was to conduct an economic analysis of two drug regi-
mens for rheumatoid arthritis and osteoarthritis: regimen
A (meloxicam 7.5 mg/day) regimen B (diclofenac 100
mg/day). METHODS: Decision-analysis was performed.
Clinical efficacy and probability of side effects was taken
from multicenter clinical trials. Costs of baseline treat-
ment and cost of treatment for side effects were analyzed.
RESULTS: Clinical efficacy in both regimens was equal.
Probability of side effects was 1.5 times higher in di-
clofenac than meloxicam (0.031 vs 0.019) according to
the trials. Cost of standard treatment for side effects was
$6.80 US for minor symptoms, $12.20 US for ulcer at
out-patient department, and $188.04 US for ulcer at hos-
pital. Such low costs are explained with low levels of
prices for medical services in the system of medical insur-
ance. Cost of period of treatment including treatment for
side effects was $20.09 US for diclofenac and $15.42 US
for meloxicam. CONCLUSIONS: Treatment with meloxi-
cam was cheaper than with diclofenac, but the difference
was mostly explained by the price of drugs, because
prices for medical services are very low in Russia. Pres-
ently in this country drug prices are most important, as
they are determined by market forces while prices for
medical services are regulated by the state and are low
because of limited resources.
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The introduction of celecoxib has led to the assumption that
utilization of antiulcerants may be reduced. OBJECTIVE:
The purpose of this clinical practice study was to assess
the cost benefit of switching arthritis patients from non-
steroidal anti-inflammatory drugs (NSAIDs) and con-
comitant antiulcerants to celecoxib. METHODS: 190 male
and female (67%) patients with osteoarthritis (157) or
rheumatoid arthritis (33) who were either maintained on an
NSAID or who could not tolerate prescription NSAIDs at
the baseline visit, were evaluated in this prospective, open-
label, nonrandomized study. Patients were switched or
started on celecoxib and counseled by the prescribing
physician to discontinue any antiulcerants and limit use
of OTC NSAIDs. Patients returned for 2 monthly follow-
up visits for further assessments and tabulation of con-
comitant drug use. RESULTS: Of the 110 patients
treated with traditional NSAIDs and/or disease modify-
ing agents, 25% were maintained on ibuprofen, 19% on
aspirin, and 13% were maintained on nabumetone or
diclofenacmisoprostol. 82 patients were taking a pro-
ton pump inhibitor (omeprazole [30] or lansoprazole
[14]), histamine antagonist (ranitidine [12] or famotidine
[11]), or misoprostol (9). Over a 3 month follow-up period,
71 (87%) of these patients had discontinued the antiul-
cerants at time of switching to celecoxib. Based upon AWP
pricing, the switch to celecoxib with discontinuation in
antiulcerants resulted in an average daily savings of $2.65
US per patient. CONCLUSION: Appropriate switching of
arthritic patients from their traditional NSAID and anti-
ulcerant to celecoxib results in a significant cost savings
to the patient and managed care organization.
